Latest CervoMed News & Updates

See the latest news and media coverage for CervoMed. We track all announcements, press releases, and industry mentions in real time, all in one place.

CervoMed

Clinical-stage biotechnology company developing treatments for age-related brain disorders

cervomed.com

Headquarters: Boston, United States
Founded year: 2023
Company type: Public company
Number of employees: 20–50
Industry: Pharmaceuticals

Last updated Today

Latest news about CervoMed

In short: CervoMed advanced its lead candidate neflamapimod toward Phase 3 trials for dementia with Lewy bodies following alignment with the FDA.

Company announcements

July 14 CervoMed

CervoMed presents new clinical data for neflamapimod at AAIC 2026

New analyses reinforce treatment effect in pure DLB and support Phase 3 dose selection.

July 9 CervoMed

CervoMed completes enrollment in Phase 2 study for nfvPPA

Interim biomarker data accepted for CTAD presentation. No approved treatments exist for this FTD type.

June 22 CervoMed

CervoMed closes $10 million registered direct offering

The offering of 2.5 million shares at $4.00 per share was placed by H.C. Wainwright & Co. and proceeds will be used for working capital.

June 10 CervoMed

CervoMed announces private placement financing and partnering plan

The $10.5M raise extends runway to Q2 2027 and supports partnership to move neflamapimod into Phase 3 for DLB.

Media coverage

July 9 Markets Insider

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

Interim biomarker data accepted for presentation at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conferenceRecent peer-reviewed data...

June 18 The Globe and Mail

CervoMed Raises $10 Million in Direct Offering

On June 22, 2026, CervoMed Inc. closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising gross proceeds of...

June 18 Yahoo Finance

CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO)

CervoMed Inc. (NASDAQ:CRVO) shares climbed 20% on Thursday after the company announced it had received a notice of allowance from the U.

June 16 Timothy Sykes

CRVO Stock Explodes As Insider Buy Fuels Biotech Momentum

CervoMed Inc. surged as promising neurodegenerative trial data boosted sentiment; stocks have been trading up by 19.95 percent. Key Takeaways CervoMed is raising about $10.5M...

Never miss news about CervoMed

Track CervoMed and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.